Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
eNq1mFFv2jAQx9/5FFHeSSBrgU6BamOwIbUao0Wb9oJMchSzYKdnG+g+/RxCNTo56mrwG8TO/86+v38+Jb7erTNvAygoZ12/GTR8D1jCU8oeuv70fljv+Ne9WrwiG3I0Tc8Losj3kowI0fWL0WAOhIngx+3NJ9DvA/q9mhfz+QoS+WKekjQLvhCxvCV5MceLN5ym3hrkkqddP1dy/9SLhUSdRW/L8ZfISQJxeHhyPLqaXRw/j8NC7D9UlQC8IezBKArMSjNRiMBkn0h44PhUke87K20qJiC4wgTGRC7HyDc0hdQYYkEyAVZBFtv0DnCTgSyCGMXDVbIWVuJkRXYTeByZk/6gR/tyJ+uNerPdvGhH7U4jihoNq1B4tFXmKuhFhMms02q1r6IQ2H5Voa5N8Rs5l5Y1GnOUJHNUHSr6Lw3mKA7C46suSKnIM/IUrERuu1UEiR4G1Bhwt5BiBfeowZTpPftHn6ksC9+Y9fSADUcZF1Tqc8VkBT2GE9uN6HMmYVddUTvgyd3BixTE+WR/c2aG/VjNM5rYok3DR4GQ08mommwuoPCRCJiiOyp8pyzlW3F+2hxX11H2+R6YRtEc0+Ysuuq0mpeX1ofpp7ZSxY0zUMhzCDWHqDgFLyO24KeCRbvTLPXszbPbct//8IRkUNEBzSxZo/343LA5c7y701QOGEU/D+5tbfJNAT7d7f8apWnafS6wHYddwF17sjLvtzu8POhOWmOFZoAspczF+zDcbrfBkoi6IHqXggU6A/3RHeuuQXdykZeNTQlLR6nPy1vwbZWyPXCvXfWntq+H9w9tsjGGRAUn1KJkszOCjgbnh/Lf3tVZ2uMXFHEXZt9nEkk5c9X3qLlR8aRrQJeVDVHz4etiQSu+l1TaMg7LbzW9WhwW32l6tT8rku9k
1XvfUhJ4LNgHP7F3